Evidence map›Paper›PMID 33245660›Full record

ArticleJournal of psychiatry & neuroscience : JPN2021

11β-Hydroxylase (CYP11B1) gene variants and new-onset depression in later life.

Marie-Laure Ancelin, Joanna Norton, Karen Ritchie, Isabelle Chaudieu, Joanne Ryan

Open access · diamondAbstract read
In one paragraph

Article in Journal of psychiatry & neuroscience : JPN, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Frontiers in neuroscience · 2022
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Marie-Laure AncelinFrom Inserm, Université Montpellier, Neuropsychiatry: Epidemiological and Clinical Research, Montpellier, France (Ancelin, Norton, Ritchie, Chaudieu, Ryan); the Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom (Ritchie); and the Biological Neuropsychiatry and Dementia Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia (Ryan).
Joanna NortonFrom Inserm, Université Montpellier, Neuropsychiatry: Epidemiological and Clinical Research, Montpellier, France (Ancelin, Norton, Ritchie, Chaudieu, Ryan); the Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom (Ritchie); and the Biological Neuropsychiatry and Dementia Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia (Ryan).
Karen RitchieFrom Inserm, Université Montpellier, Neuropsychiatry: Epidemiological and Clinical Research, Montpellier, France (Ancelin, Norton, Ritchie, Chaudieu, Ryan); the Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom (Ritchie); and the Biological Neuropsychiatry and Dementia Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia (Ryan).
Isabelle ChaudieuFrom Inserm, Université Montpellier, Neuropsychiatry: Epidemiological and Clinical Research, Montpellier, France (Ancelin, Norton, Ritchie, Chaudieu, Ryan); the Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom (Ritchie); and the Biological Neuropsychiatry and Dementia Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia (Ryan).
Joanne RyanFrom Inserm, Université Montpellier, Neuropsychiatry: Epidemiological and Clinical Research, Montpellier, France (Ancelin, Norton, Ritchie, Chaudieu, Ryan); the Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom (Ritchie); and the Biological Neuropsychiatry and Dementia Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia (Ryan).
Université de Montpellier · FRUniversity of Edinburgh · GBNeuropsychiatrie : Recherche Epidemiologique et Clinique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cumulative exposure to high glucocorticoid levels is detrimental for the brain and may have particular implications in later life. A feature of late-life depression is increased cortisol secretion. Variants in the CYP11B1 gene, which codes for the enzyme responsible for cortisol synthesis, could influence risk of late-life depression, but this hypothesis has not been examined. We investigated the associations between variants in the CYP11B1 gene and late-life depression, taking into account history of depression and potential sex-specific effects. Methods: We assessed depression in 1007 community-dwellers aged 65 years or older (60% women) at baseline and over a 14-year follow-up. A clinical level of depression was defined as a score of ≥ 16 on the Centre for Epidemiology Studies Depression scale or a diagnosis of current major depression based on the Mini-International Neuropsychiatric Interview and according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). We examined incident and recurrent depression in participants without or with a history of major depression, respectively. We genotyped 5 single-nucleotide polymorphisms (SNPs) spanning CYP11B1. We used multivariable analyses to adjust for age, body mass index, cardiovascular ischemic pathologies, hypertension, cognitive impairment and anxiety. Results: In women, rs6471580 and rs7016924 were associated with a 50% lower rate of incident (new-onset) late-life depression, and rs11783855 was associated with a 2.4-fold higher rate of late-life depression. These associations remained after correction for multiple testing, but we found no associations for recurrent depression in women or men. Limitations: This study focused on the major gene involved in corticosteroid biosynthesis, but other genes may also be implicated in this pathway. Conclusion: Variants of the CYP11B1 gene appear to be susceptibility factors for late-life depression in a sex-specific manner.

Indexed as

AgedAged, 80 and overAgingAnxiety DisordersComorbidityDepressive DisorderFemaleFranceGenetic Predisposition to DiseaseHumansIncidenceIndependent LivingLongitudinal StudiesMajor Depressive DisorderMaleObesitySteroid 11-beta-Hydroxylase

Identifiers

PMID33245660
PMCPMC7955840
OpenAlexW3109563710

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.